CPG
RPRX icon

Cornerstone Planning Group’s Royalty Pharma RPRX Stock Holding History

Cornerstone Planning Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9K Sell
373
-29
-7% -$1.51K ﹤0.01% 653
2026
Q1 		$20.2K Buy
402
+106
+36% +$4.64K ﹤0.01% 663
2025
Q4 		$12K Sell
296
-235
-44% -$8.96K ﹤0.01% 748
2025
Q3 		$57.7K Buy
531
+406
+325% +$14.7K 0.01% 307
2025
Q2 		$4.74K Buy
125
+25
+25% +$828 ﹤0.01% 738
2025
Q1 		$3.17K Buy
100
+53
+113% +$1.68K ﹤0.01% 863
2024
Q4 		$1.49K Buy
+47
New +$1.25K ﹤0.01% 868

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cornerstone Planning Group's RPRX Position: Q2 2026 in Review

Cornerstone Planning Group reduced its Royalty Pharma (RPRX) stake by 7.2% in Q2 2026, selling an estimated $1.51K and leaving 373 shares worth $21.9K. The position accounts for ﹤0.01% of the portfolio, ranked #653.

Cornerstone Planning Group first reported a position in RPRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $57.7K in Q3 2025. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Cornerstone Planning Group held 373 shares of Royalty Pharma worth $21.9K as of Q2 2026.
  • Cornerstone Planning Group sold 29 Royalty Pharma shares in Q2 2026, an estimated $1.51K.
  • Royalty Pharma made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #653 holding.
  • Cornerstone Planning Group first reported a position in Royalty Pharma in Q4 2024 and has held it in 7 quarters since.
  • Cornerstone Planning Group's Royalty Pharma position peaked at $57.7K in Q3 2025.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.